Voriconazole as Prophylactic Therapy in Lung Transplant Recipients

Assessment of Safety and Efficacy of Voriconazole as Prophylactic Antifungal Therapy for Lung Transplant Recipients

The purpose of this study is to compare the safety and efficacy of Voriconazole with Itraconazole following lung transplantation.

All participants will receive itraconazole during their inpatient post transplant stay. As an outpatient, ten subjects will be randomized to receive itraconazole 200mg orally once daily for 6 month and ten patients to receive voriconazole 200mg orally twice daily for 6 months . All subjects will be followed in the clinic as per the standard transplant treatment

Inclusion Criteria:

• Bilateral-lung or single-lung transplant recipients between the ages of 18- 65 years old.
• Patients must be able to give informed consent prior to and again after transplantation

Exclusion Criteria:

• Lung transplant patients unable to give informed consent.
• Prior adverse reaction to the drug itraconazole or voriconazole